MCID: CRH001
MIFTS: 79

Crohn's Disease

Categories: Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Crohn's Disease

MalaCards integrated aliases for Crohn's Disease:

Name: Crohn's Disease 39 12 77 54 26 44 15 17
Crohn Disease 12 26 38 6 15 74
Pediatric Crohn's Disease 12 54 74
Enteritis 54 56 74
Crohn's Disease of Large Bowel 12 74
Granulomatous Colitis 12 54
Ileitis 54 74
Pediatric Onset Crohn's Disease 54
Crohn's Disease, Pediatric 54
Crohn's Disease of Colon 12
Enteritis, Granulomatous 26
Granulomatous Enteritis 54
Colitis, Granulomatous 26
Enteritis, Regional 26
Regional Enteritis 74
Crohn's Enteritis 26

Classifications:



External Ids:

Disease Ontology 12 DOID:8778
KEGG 38 H00286
ICD9CM 36 555.1
MeSH 45 D003424
SNOMED-CT 69 50440006 7620006

Summaries for Crohn's Disease

NIH Rare Diseases : 54 Crohn's disease is a type of inflammatory bowel disease (IBD), the general name for conditions that cause inflammation in the gastrointestinal (GI) tract. Common signs and symptoms include abdominal pain and cramping, diarrhea, and weight loss. Other general symptoms include feeling tired, nausea and loss of appetite, fever, and anemia. Complications of Crohn's disease may include intestinal blockage, fistulas, anal fissures, ulcers, malnutrition, and inflammation in other areas of the body. Crohn's disease can occur in people of all age groups but is most often diagnosed in young adults. The exact cause is unknown, but is thought to be due from a combination of certain genetic variations, changes in the immune system, and the presence of bacteria in the digestive tract.  Many of the major genes related to Crohn disease, including NOD2, ATG16L1, IL23R, and IRGM, are involved in immune system function. The disease is not inherited but it appears to run in some families because in about 15% of the cases the disease is present in more than one relative.  Treatment is aimed at relieving symptoms and reducing inflammation, and may include diet and medication, but some people require surgery. Surgery often involves removal of the diseased segment of bowel (resection), the two ends of healthy bowel are then joined together (anastomosis). In about 30% of people who have surgery for Crohn�??s disease symptoms may come back within three years and up to 60% will have recurrence within ten years.

MalaCards based summary : Crohn's Disease, also known as crohn disease, is related to inflammatory bowel disease 25, autosomal recessive and ulcerative colitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Crohn's Disease is ENSG00000278769 (), and among its related pathways/superpathways are NOD-like receptor signaling pathway and Cytokine-cytokine receptor interaction. The drugs Adalimumab and Infliximab have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 An intestinal disease that involves inflammation located in intestine.

MedlinePlus : 44 Crohn's disease causes inflammation of the digestive system. It is one of a group of diseases called inflammatory bowel disease. Crohn's can affect any area from the mouth to the anus. It often affects the lower part of the small intestine called the ileum. The cause of Crohn's disease is unknown. It may be due to an abnormal reaction by the body's immune system. It also seems to run in some families. It most commonly starts between the ages of 13 and 30. The most common symptoms are pain in the abdomen and diarrhea. Other symptoms include Bleeding from the rectum Weight loss Fever Your doctor will diagnose Crohn's disease with a physical exam, lab tests, imaging tests, and a colonoscopy. Crohn's can cause complications, such as intestinal blockages, ulcers in the intestine, and problems getting enough nutrients. People with Crohn's can also have joint pain and skin problems. Children with the disease may have growth problems. There is no cure for Crohn's. Treatment can help control symptoms, and may include medicines, nutrition supplements, and/or surgery. Some people have long periods of remission, when they are free of symptoms. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Wikipedia : 77 Crohn''s disease is a type of inflammatory bowel disease (IBD) that may affect any part of the... more...

Related Diseases for Crohn's Disease

Diseases related to Crohn's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1429)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 25, autosomal recessive 32.3 IL10RA IL10RB
2 ulcerative colitis 30.9 ABCB1 ATG16L1 IL10RA IL10RB IL23R IRF5
3 colitis 30.9 ABCB1 ATG16L1 DUOX2 IL10RA IL10RB IL23R
4 inflammatory bowel disease 30.9 ABCB1 ATG16L1 IL10RA IL10RB IL18RAP IL23R
5 inflammatory bowel disease 5 30.7 ATG16L1 IL23R NOD2 SLC22A4 SLC22A5
6 psoriatic arthritis 30.4 IL23R NOD2 S100A12
7 rheumatoid arthritis 30.4 IRF5 LACC1 S100A12 SLC11A1 SLC22A4
8 leprosy 3 30.3 LACC1 NOD2 SLC11A1
9 inflammatory bowel disease 1 30.3 NOD2 SLC22A4 SLC22A5
10 spondylarthropathy 30.3 HP NOD2
11 intestinal disease 30.3 ATG16L1 IL23R NOD2
12 thoraco abdominal enteric duplication 12.4
13 gastroduodenal crohn's disease 12.4
14 crohn's disease of the esophagus 12.3
15 enteric pattern testicular yolk sac tumor 12.1
16 trichohepatoenteric syndrome 1 12.1
17 diarrhea 4, malabsorptive, congenital 11.6
18 melkersson-rosenthal syndrome 11.5
19 pyoderma gangrenosum 11.4
20 orofacial granulomatosis 11.4
21 diarrhea 11.4
22 colorectal cancer 11.4
23 epidermolysis bullosa acquisita 11.4
24 pulmonary alveolar microlithiasis 11.4
25 keratomalacia 11.4
26 littoral cell angioma of the spleen 11.4
27 coccidiosis 11.3
28 hirschsprung disease 1 11.3
29 amebiasis 11.3
30 campylobacteriosis 11.3
31 head injury 11.3
32 aspiration pneumonia 11.3
33 visceral myopathy 11.3
34 hermansky-pudlak syndrome 4 11.2
35 hermansky-pudlak syndrome 5 11.2
36 inflammatory bowel disease 29 11.2
37 brain injury 11.2
38 trichinosis 11.2
39 traumatic brain injury 11.2
40 sleeping sickness 11.2
41 gastrointestinal tularemia 11.2
42 chagas disease 11.1
43 anthrax disease 11.1
44 hirschsprung disease 2 11.1
45 cysticercosis 11.1
46 tularemia 11.1
47 erythromelalgia 11.1
48 inflammatory bowel disease 13 11.1
49 inflammatory bowel disease 14 11.1
50 inflammatory bowel disease 28, autosomal recessive 11.1

Comorbidity relations with Crohn's Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Inflammatory Bowel Disease 1
Intestinal Obstruction Protein-Energy Malnutrition
Ulcerative Colitis

Graphical network of the top 20 diseases related to Crohn's Disease:



Diseases related to Crohn's Disease

Symptoms & Phenotypes for Crohn's Disease

UMLS symptoms related to Crohn's Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Crohn's Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 ABCB1 ATG16L1 HP IL10RA IL10RB IL18RAP
2 digestive/alimentary MP:0005381 9.86 ABCB1 ATG16L1 IL10RA IL10RB IL23R NOD2
3 homeostasis/metabolism MP:0005376 9.77 ABCB1 ATG16L1 DUOX2 HP IL10RA IL10RB
4 immune system MP:0005387 9.4 ABCB1 ATG16L1 HP IL10RA IL10RB IL18RAP

Drugs & Therapeutics for Crohn's Disease

Drugs for Crohn's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 469)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
2
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
3
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable 50-23-7 5754
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
5
Hydrocortisone acetate Approved, Vet_approved Phase 4,Not Applicable 50-03-3
6
Clarithromycin Approved Phase 4,Phase 3 81103-11-9 84029
7
Clofazimine Approved, Investigational Phase 4,Phase 3 2030-63-9 2794
8
Rifabutin Approved, Investigational Phase 4,Phase 3 72559-06-9 46783538 6323490
9
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
11
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
13
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 428863-50-7
14
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 27284 23925
15
Prucalopride Approved Phase 4 179474-81-8
16
Mercaptopurine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-44-2 667490
17
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 446-86-6 2265
18
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 443-48-1 4173
19
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
20
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
21
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
22
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
23
Azithromycin Approved Phase 4 83905-01-5 447043 55185
24
Methotrexate Approved Phase 4,Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
25
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1 51333-22-3 5281004 63006
26 Vedolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 943609-66-3
27
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
28
Etidronic acid Approved Phase 4 7414-83-7, 2809-21-4 3305
29
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
30
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 189261-10-7
31 Menaquinone Approved, Investigational Phase 4,Phase 1 1182-68-9
32
Phylloquinone Approved, Investigational Phase 4,Phase 1 84-80-0
33
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
34
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
35
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
36
Bupivacaine Approved, Investigational Phase 4,Not Applicable 38396-39-3, 2180-92-9 2474
37
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
38
Ustekinumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 815610-63-0
39
Ondansetron Approved Phase 4,Phase 3 99614-02-5 4595
40
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
41
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 5284616 6436030
42
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 93-14-1 3516
43
Caffeine Approved Phase 4,Phase 1 58-08-2 2519
44
Dextromethorphan Approved Phase 4,Phase 1 125-71-3 5362449 5360696
45
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
46
Losartan Approved Phase 4 114798-26-4 3961
47
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 50-02-2 5743
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 1177-87-3
49
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
50
Vancomycin Approved Phase 4,Phase 2 1404-90-6 14969 441141

Interventional clinical trials:

(show top 50) (show all 1321)
# Name Status NCT ID Phase Drugs
1 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
2 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
3 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
4 Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
5 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission Unknown status NCT01817426 Phase 4 Infliximab
6 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
7 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
8 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
9 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
10 VSL#3 Treatment in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
11 Optimizing Cimzia in Crohn's Patients Unknown status NCT01024647 Phase 4
12 Does Clinical Response Correlate With Serum Certolizumab Levels? Unknown status NCT02597829 Phase 4 Certolizumab Pegol
13 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
14 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
15 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
16 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
17 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
18 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
19 Prucalopride Prior to Small Bowel Capsule Endoscopy Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
20 SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD). Completed NCT02199626 Phase 4
21 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
22 Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease Completed NCT02148718 Phase 4
23 Trial of a Treatment Algorithm for the Management of Crohn's Disease Completed NCT01030809 Phase 4
24 Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease Completed NCT00588653 Phase 4
25 A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease Completed NCT00225810 Phase 4 Crohn's Disease
26 Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease Completed NCT01442025 Phase 4 Infliximab;Infliximab;Infliximab
27 The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy Completed NCT01181765 Phase 4
28 VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease Completed NCT00114465 Phase 4 VSL#3
29 Evaluation of the Applicability of the CDEIS to Data Obtained by the Colonic Capsule Endoscopy in Crohn Disease Completed NCT01183845 Phase 4
30 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery Completed NCT00688636 Phase 4 infliximab;placebo
31 Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease Completed NCT01596894 Phase 4 Azithromycin + Metronidazole;Metronidazole
32 Top Down Versus Step Up Strategies in Crohn's Disease Completed NCT00554710 Phase 4 infliximab+azathioprine;methylprednisolone or budesonide
33 Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial Completed NCT02256462 Phase 4 Adalimumab
34 Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease Completed NCT02630966 Phase 4 Vedolizumab;Placebo
35 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease Completed NCT02010762 Phase 4 Vitamin D;Placebo
36 Vitamin D Supplementation in Adult Crohn's Disease Completed NCT01369667 Phase 4
37 Adalimumab-psoriasis and Small Bowel Lesions Completed NCT01556672 Phase 4 Adalimumab
38 Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease Completed NCT01215890 Phase 4 risedronate;placebo
39 Early Immunosuppressants in Crohn's Disease Completed NCT00546546 Phase 4 early immunosuppressants (azathioprine, methotrexate)
40 Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease Completed NCT00280956 Phase 4 natalizumab
41 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Completed NCT02559713 Phase 4 Vedolizumab
42 Vitamin D in Pediatric Crohn's Disease Completed NCT01187459 Phase 4
43 Pneumococcal Vaccination of Crohn Patients Completed NCT01947010 Phase 4
44 The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients Completed NCT01235325 Phase 4
45 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
46 Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease Completed NCT02349594 Phase 4 Omegaven 10%;Intralipid 20%
47 Vitd and Barrier Function in IBD Completed NCT01792388 Phase 4
48 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
49 Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation Completed NCT02269358 Phase 4 METHOTREXATE
50 Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas Completed NCT00517296 Phase 4 adalimumab

Search NIH Clinical Center for Crohn's Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Crohn's Disease cell therapies at LifeMap Discovery.

Genetic Tests for Crohn's Disease

Anatomical Context for Crohn's Disease

MalaCards organs/tissues related to Crohn's Disease:

42
Colon, Bone, T Cells, Skin, Testes, Small Intestine, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Crohn's Disease:

20
Intestine
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Crohn's Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Crohn's Disease

Articles related to Crohn's Disease:

(show top 50) (show all 8407)
# Title Authors Year
1
Acute myocardial infarction in a patient with a recent diagnosis of Crohn's disease. ( 29954623 )
2019
2
Acute pancreatitis associated with indigo naturalis in pediatric severe Crohn's disease. ( 30317857 )
2019
3
Multifocal small-bowel adenocarcinoma mimicking Crohn's disease. ( 31102641 )
2019
4
Multidisciplinary management of complicated small bowel adenocarcinoma on the ground of Crohn's disease. ( 30942003 )
2019
5
Adenocarcinoma within anorectal fistulae: different clinicopathological characteristics between Crohn's disease-associated type and the usual type. ( 30206406 )
2019
6
Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. ( 31012051 )
2019
7
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. ( 30739254 )
2019
8
Adalimumab-induced autoimmune hepatitis in a patient with Crohn's disease. ( 30029925 )
2019
9
Behçet Syndrome and Crohn's Disease: What Are the Differences? ( 30931276 )
2019
10
Cheilitis and gingivitis as first signs of Crohn's disease in a pediatric patient. ( 30847214 )
2019
11
Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension with active Crohn's disease. ( 30976945 )
2019
12
Endoscopy in Postoperative Patients with Crohn's Disease or Ulcerative Colitis. Does It Translate to Better Outcomes? ( 31078249 )
2019
13
Strictures in Crohn's Disease and Ulcerative Colitis: Is There a Role for the Gastroenterologist or Do We Always Need a Surgeon? ( 31078252 )
2019
14
Markers of dysbiosis in patients with ulcerative colitis and Crohn's disease. ( 31094471 )
2019
15
A specific gene-microbe interaction drives the development of Crohn's disease-like colitis in mice. ( 31004013 )
2019
16
Metaproteomics of fecal samples of Crohn's disease and Ulcerative Colitis. ( 31009805 )
2019
17
A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease. ( 31054010 )
2019
18
Immunoglobulin G4-related immune responses to common food antigens in patients with ulcerative colitis and Crohn's disease. ( 31060995 )
2019
19
Perceived distress, personality characteristics, coping strategies and psychosocial impairments in a national German multicenter cohort of patients with Crohn's disease and ulcerative colitis. ( 30965377 )
2019
20
Best practices on immunomodulators and biological agents for Ulcerative colitis and Crohn's disease in Asia. ( 30848854 )
2019
21
Malassezia Is Associated with Crohn's Disease and Exacerbates Colitis in Mouse Models. ( 30850233 )
2019
22
Diffuse colitis cystica profunda in Crohn's disease: A potential diagnostic pitfall. ( 30856259 )
2019
23
Distinct patterns of naïve, activated and memory T and B cells in blood of patients with ulcerative colitis or Crohn's disease. ( 30883691 )
2019
24
Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis. ( 30908719 )
2019
25
Untargeted Metabolomics and Inflammatory Markers Profiling in Children With Crohn's Disease and Ulcerative Colitis-A Preliminary Study. ( 30772902 )
2019
26
Depression and resilience in ulcerative colitis and Crohn's disease patients with ostomy. ( 30793856 )
2019
27
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis. ( 30830573 )
2019
28
Backwash ileitis in ulcerative colitis: Are there MR enterographic features that distinguish it from Crohn disease? ( 30599862 )
2019
29
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. ( 30625408 )
2019
30
Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohn's Disease and Ulcerative Colitis. ( 30496425 )
2019
31
Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon Transcriptome. ( 30517639 )
2019
32
Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis. ( 30333413 )
2019
33
The Human Mesenteric Lymph Node Microbiome Differentiates Between Crohn's Disease and Ulcerative Colitis. ( 30239655 )
2019
34
Enteric Virome and Bacterial Microbiota in Children With Ulcerative Colitis and Crohn Disease. ( 30169455 )
2019
35
The Risk of Elective Abortion in Women With Crohn's Disease and Ulcerative Colitis: A Nationwide Cohort Study. ( 30107577 )
2019
36
Association of T Helper 1 Cytokine Gene Single Nucleotide Polymorphisms with Ulcerative Colitis and Crohn's Disease. ( 30134230 )
2019
37
Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center. ( 30134234 )
2019
38
Altered uric acid metabolism in isolated colonic Crohn's disease but not ulcerative colitis. ( 29926959 )
2019
39
Prediagnostic Serum Vitamin D Levels and the Risk of Crohn's Disease and Ulcerative Colitis. ( 29788234 )
2019
40
No Association Between Consumption of Sweetened Beverages and Risk of Later-Onset Crohn's Disease or Ulcerative Colitis. ( 29751165 )
2019
41
miR-192/215-5p act as tumor suppressors and link Crohn's disease and colorectal cancer by targeting common metabolic pathways: An integrated informatics analysis and experimental study. ( 31020657 )
2019
42
Safety of drugs used for the treatment of Crohn's disease. ( 31026401 )
2019
43
The Unique Lifestyle of Crohn's Disease-Associated Adherent Invasive Escherichia coli. ( 31029703 )
2019
44
Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn's Disease: A Systematic Review. ( 31030304 )
2019
45
Characteristics of polymeric formula and route of delivery of exclusive enteral nutrition have no effect on disease outcome and weight gain in pediatric Crohn's disease. ( 31031135 )
2019
46
Preliminary study of short- and long-term outcome and quality of life after minimally invasive surgery for Crohn's disease: Comparison between single incision, robotic-assisted and conventional laparoscopy. ( 31031322 )
2019
47
Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients. ( 31032686 )
2019
48
Effectiveness of infliximab biosimilar in Crohn's disease: a dime, a dozen. ( 31034829 )
2019
49
The present state and future direction of regenerative Medicine for perianal Crohn's disease. ( 31034831 )
2019
50
Inflammation associated ethanolamine facilitates infection by Crohn's disease-linked adherent-invasive Escherichia coli. ( 31036531 )
2019

Variations for Crohn's Disease

Expression for Crohn's Disease

LifeMap Discovery
Genes differentially expressed in tissues of Crohn's Disease patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 REG1A regenerating islet-derived 1 alpha Colon + 4.42 0.002
2 CXCL2 chemokine (C-X-C motif) ligand 2 Colon + 4.02 0.000
3 REG1B regenerating islet-derived 1 beta Colon + 3.99 0.008
4 LCN2 lipocalin 2 Colon + 3.90 0.000
5 REG3A regenerating islet-derived 3 alpha Colon + 3.74 0.026
6 CXCL11 chemokine (C-X-C motif) ligand 11 Colon + 3.70 0.016
7 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) Colon + 3.60 0.000
8 CXCL8 chemokine (C-X-C motif) ligand 8 Colon + 3.50 0.004
9 DEFA6 defensin, alpha 6, Paneth cell-specific Colon + 3.49 0.029
10 S100A8 S100 calcium binding protein A8 Colon + 3.04 0.017
Search GEO for disease gene expression data for Crohn's Disease.

Pathways for Crohn's Disease

Pathways related to Crohn's Disease according to KEGG:

38
# Name Kegg Source Accession
1 NOD-like receptor signaling pathway hsa04621
2 Cytokine-cytokine receptor interaction hsa04060
3 JAK-STAT signaling pathway hsa04630
4 Inflammatory bowel disease (IBD) hsa05321
5 Autophagy - animal hsa04140

GO Terms for Crohn's Disease

Cellular components related to Crohn's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.77 ABCB1 CEACAM6 DUOX2 IL10RA IL10RB IL18RAP
2 autophagosome membrane GO:0000421 9.16 ATG16L1 IRGM
3 apical plasma membrane GO:0016324 9.02 ABCB1 CEACAM6 DUOX2 SLC22A4 SLC22A5

Biological processes related to Crohn's Disease according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.98 IL23R INAVA IRF5 IRGM NOD2
2 innate immune response GO:0045087 9.88 IL23R INAVA IRF5 IRGM NOD2 S100A12
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 IL18RAP NOD2 S100A12
4 defense response GO:0006952 9.79 HP IRGM NOD2
5 defense response to bacterium GO:0042742 9.77 HP IRGM NOD2 S100A12 SLC11A1
6 defense response to Gram-negative bacterium GO:0050829 9.74 IL23R IRGM SLC11A1
7 inflammatory response GO:0006954 9.73 IL10RB IL18RAP IL23R IRGM S100A12 SLC11A1
8 positive regulation of interleukin-12 production GO:0032735 9.61 IL23R IRF5
9 positive regulation of interleukin-10 production GO:0032733 9.6 INAVA NOD2
10 response to interferon-gamma GO:0034341 9.59 IL23R SLC11A1
11 positive regulation of interleukin-17 production GO:0032740 9.58 IL23R NOD2
12 positive regulation of interleukin-1 beta production GO:0032731 9.56 INAVA NOD2
13 positive regulation of T-helper 1 type immune response GO:0002827 9.55 IL23R SLC11A1
14 positive regulation of dendritic cell antigen processing and presentation GO:0002606 9.54 NOD2 SLC11A1
15 response to peptidoglycan GO:0032494 9.52 INAVA IRF5
16 carnitine transport GO:0015879 9.51 SLC22A4 SLC22A5
17 positive regulation of stress-activated MAPK cascade GO:0032874 9.5 IL26 INAVA NOD2
18 protein lipidation involved in autophagosome assembly GO:0061739 9.49 ATG16L1 IRGM
19 quaternary ammonium group transport GO:0015697 9.48 SLC22A4 SLC22A5
20 carnitine transmembrane transport GO:1902603 9.46 SLC22A4 SLC22A5
21 cytokine production involved in immune response GO:0002367 9.43 INAVA NOD2
22 cytokine-mediated signaling pathway GO:0019221 9.43 DUOX2 IL10RA IL10RB IL23R IL26 IRF5
23 response to muramyl dipeptide GO:0032495 9.33 INAVA IRF5 NOD2
24 drug transmembrane transport GO:0006855 9.31 SLC22A5
25 nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070431 8.8 INAVA IRGM NOD2

Molecular functions related to Crohn's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transporter activity GO:0005215 9.43 ABCB1 SLC22A4 SLC22A5
2 CARD domain binding GO:0050700 9.32 IRGM NOD2
3 quaternary ammonium group transmembrane transporter activity GO:0015651 9.16 SLC22A4 SLC22A5
4 carnitine transmembrane transporter activity GO:0015226 8.96 SLC22A4 SLC22A5
5 interleukin-10 receptor activity GO:0004920 8.62 IL10RA IL10RB

Sources for Crohn's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....